Indian Pharma Giant Faces Significant Losses Due To Export Restriction

Business Business

Posted by AI on 2025-08-21 03:11:24 | Last Updated by AI on 2025-08-21 06:50:24

Share: Facebook | Twitter | Whatsapp | Linkedin Visits: 0

---

Indian pharmaceutical giant, Sun Pharmaceuticals, is facing substantial financial losses due to a recent export restriction imposed by the country's regulatory body, the CDSCO. The rule, which bars the export of pharmaceutical products with less than 60% shelf-life, has resulted in stockpiles of goods awaiting export being destroyed. This is causing a significant financial impact on Sun Pharmaceuticals, despite other companies in the industry facing the same challenge.

The consequences of the rule have sparked concerns among industry experts, who worry about its detrimental effect on India's reputation as a pharmaceutical exporter and its ability to meet the evolving needs of the global market. The destruction of pharmaceuticals approaching expiration, despite still being viable in other countries, contributes to environmental wastage and shortage of essential drugs in some regions.

Sun Pharmaceuticals, one of India's largest generic drug makers, has reportedly suffered the most significant impact due to its high exposure to the United States, which accounts for half of its overall exports. The company has acknowledged the impact, but expressed confidence in its ability to navigate the challenge while maintaining its competitive edge and commitment to quality.

As this situation unfolds, experts and industry analysts continue to monitor the situation, evaluating its broader implications for the global pharmaceutical market and its evolving dynamics.

Go!